FN3.F Racura Oncology Ltd

Healthcare Biotechnology Frankfurt Exchange
0.9850 EUR
Close of Nov 11, 2026
0.8550 2.02
Market cap
EUR 193M
P/E
-
P/B
7.47x
ROE
-30.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is FN3.F undervalued?

Graham number

The Graham number of Racura Oncology Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Racura Oncology Ltd fundamental analysis

No fundamental analysis for Racura Oncology Ltd yet.

Racura Oncology Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Racura Oncology Ltd

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and change…

Full company profile